What is William Blair’s Estimate for Genmab A/S Q1 Earnings?

Genmab A/S (NASDAQ:GMAB) – William Blair issued their Q1 2026 earnings per share estimates for Genmab A/S in a research report issued to clients and investors on Tuesday, March 18th. William Blair analyst M. Phipps anticipates that the company will post earnings of $0.37 per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share. William Blair also issued estimates for Genmab A/S’s Q2 2026 earnings at $0.57 EPS, Q3 2026 earnings at $0.62 EPS and Q4 2026 earnings at $0.67 EPS.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%.

GMAB has been the topic of a number of other research reports. Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research report on Thursday, February 13th. Sanford C. Bernstein raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Truist Financial dropped their price target on Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Tuesday, March 11th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. Finally, BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. Four analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Genmab A/S currently has a consensus rating of “Moderate Buy” and an average target price of $41.33.

Genmab A/S Price Performance

Shares of NASDAQ GMAB opened at $20.20 on Wednesday. Genmab A/S has a one year low of $18.64 and a one year high of $31.02. The business’s fifty day moving average price is $21.18 and its 200-day moving average price is $22.28. The stock has a market capitalization of $13.37 billion, a PE ratio of 11.61, a P/E/G ratio of 2.65 and a beta of 0.98.

Hedge Funds Weigh In On Genmab A/S

Institutional investors have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC increased its stake in Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after acquiring an additional 939 shares during the last quarter. Lindbrook Capital LLC increased its stake in Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after acquiring an additional 950 shares during the last quarter. GAMMA Investing LLC increased its stake in Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after acquiring an additional 1,051 shares during the last quarter. Barclays PLC increased its stake in Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company’s stock worth $52,000 after acquiring an additional 2,285 shares during the last quarter. Finally, Cromwell Holdings LLC increased its stake in Genmab A/S by 656.8% in the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after acquiring an additional 2,496 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.